Breaking News

Financial Reports: Roche

By Gil Roth | April 11, 2013

Roche 1Q13

1Q Revenues: $12.5 billion (+4%)

1Q Earnings: not disclosed

Comments: Pharma revenues overall rose 5% to $9.9 billion, with U.S. sales up 13% to $4.2 billion, European sales up 1% to $2.5 billion, Japanese sales down 12% to $888 million, and rest-of-world sales up 6% to $2.3 billion. Rituxan sales were up 6% to $1.8 billion; Herceptin sales rose 11% to $1.7 billion and Avastin sales climbed 11% to $1.6 billion. Tamiflu sales were up 84% to $360 million in the quarter, and Actemra climbed 32% to $256 million.
blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments